SNP Schlawien supports Vivoryon Therapeutics in capital increase of € 43 million
Together with TaylorWessing, the commercial law firm SNP Schlawien advised its long-standing client Vivoryon Therapeutics AG - formerly Probiodrug AG - on a capital increase with subscription rights. Through the rights offering to its existing shareholders and a subsequent private placement with selected investors, Vivoryon has raised capital totalling approximately € 43 million. SNP Schlawien was advised on all aspects of corporate law, while Taylor Wessing covered all capital market issues.
With this capital increase, Vivoryon has issued a total of 7,674,106 new ordinary bearer shares at a subscription price of € 5.61 per new share, which have been admitted to trading on Euronext Amsterdam. The rights offering was supported by NIBC Bank and ODDO BHF as Joint Global Coordinator.
Vivoryon Therapeutics AG specialises in novel therapeutic solutions for the treatment of neurological diseases, including Alzheimer's disease. The proceeds from this capital increase will be used in particular to finance the planned phase 2b clinical trial with the lead product PQ912 against Alzheimer's disease in Europe until the results are announced in 2022. In addition, the preparation and initiation of the Phase 2b clinical trial with PQ912 in the USA will be completed.
SNP Schlawien has been advising Vivoryon for more than 10 years and supports the company in all corporate matters, including the IPO in 2014 and three further capital increases since then.
Advisor Vivoryon Therapeutics AG
SNP Schlawien Partnerschaft mbB, Munich: Dr. Christian Ostermaier (lead), Christine Lange (both Corporate law)
Taylor Wessing Partnerschaft mbB, Frankfurt: Ulrich Reers (lead), Dr. Sebastian Beyer, Li Alena Oppenauer, Elena Quach, Brigitte Su-Lin Sommer, Tobias Kraut (all Capital Markets, Frankfurt), Dr. Manja Epping (Life Sciences, Munich)
Dr. Christian Ostermaier
Certified labor law attorney
Certified commercial and corporate law attorney
Solicitor (England and Wales)
Telephone: +49 89 28634-446